COMPASS Pathways Plc · NASDAQ:CMPS

COMPASS Pathways — Corporate Update (July 2026)

24 slides from COMPASS Pathways's corporate update, Jul 7, 2026

  1. Slide 1: Phase 3 COMP006 data review

    Compass Pathways Phase 3 COMP006 data review July 7, 2026 © Compass Pathways | 1

  2. Slide 2: Disclaimer

    Disclaimer Cautionary Note Regarding Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, you can identify forward-looking statements by terms such as “believe,” “cont

  3. Slide 3: Welcome

    Welcome Kabir Nath Chief Executive Officer Guy Goodwin, MD Chief Medical Officer Lori Englebert Chief Commercial Officer © Compass Pathways | 3

  4. Slide 4: Significant Progress Towards Potential Approval of COMP360 in TRD

    Significant Progress Towards Potential Approval of COMP360 in TRD ❖ Consistent Results across two highly statistically significant positive Phase 3 trials • COMP006 and COMP005 26-week data demonstrate rapid onset and remarkable durability through at least 6 months further validating COMP360’s diffe

  5. Slide 5: COMP360: Consistent and statistically significant positive late-stage trials in TRD

    Consistent and 3 statistically significant positive late-stage trials in TRD Robust data in over 1,000 participants Differentiated Rapid onset, remarkable durability data out to COMP360 Profile 26 weeks from Phase 3 trials COMP360: Transforming Mental Clear accelerated Rolling NDA submission/review

  6. Slide 6: COMP006 Clinical Data

    COMP006 Clinical Data © Compass Pathways | 6

  7. Slide 7: Phase 3 Program in TRD: Trial Designs

    Phase 3 Program in TRD: Trial Designs Part A (blinded) 6 weeks Part B (blinded) 20 weeks Part C (open label) 26 weeks Week 6 COMP360 Primary endpoint 25 mg achieved1 COMP360 25mg treatment COMP 005 N=171 P<0.001 option for (one dose only after relapse or for single dose retreatment* non-remitters fr

  8. Slide 8: Remarkable Consistency in COMP005 & COMP006 Through 6 Months

    Remarkable Consistency in COMP005 & COMP006 Through 6 Months* Convincing separation between Confirms validity, consistency and Clear benefit of additional dose, 25mg and control arms maintained durability of efficacy signal over 26 either as fixed dose after 3 weeks (006) over 26-weeks in both studi

  9. Slide 9: COMP006 Enrolled a Highly Chronic TRD Population

    COMP006 Enrolled a Highly Chronic TRD Population COMP360 COMP360 COMP360 COMP360 COMP360 COMP36 25 mg 10 mg 1 mg 25 mg 10 mg 0 1 mg (N=296) (N=142) (N=143) (N=296) (N=142) (N=143) Number of failed treatments in Length of current depressive episode current depressive episode, n (%) Mean Months (SD) 4

  10. Slide 10: Duration of Current Episode Strongest Predictor of Non-Response in TRD

    Duration of Current Episode Strongest Predictor of Non-Response in TRD Source: European Neuropsychopharmacology. Volume 98, September 2025, Pages 26-34 (https://www.sciencedirect.com/science/article/pii/S0924977X25001294) © Compass Pathways | 10

  11. Slide 11: Participant Baseline Demographics in Line with Known TRD Epidemiology

    Participant Baseline Demographics in Line with Known TRD Epidemiology COMP360 COMP360 COMP360 COMP006 25 mg (N=296) 10 mg (N=142) 1 mg (N=143) Female, n (%) 160 (54.1) 68 (47.9) 69 (48.3) Race, n (%) White 255 (86.1) 123 (86.6) 129 (90.2) Asian 14 (4.7) 6 (4.2) 6 (4.2) Black or African American 8 (2

  12. Slide 12: COMP006 - Rapid Onset and Sustained Durability to Week 26

    COMP006 - Rapid Onset and Sustained Durability to Week 26 Rapid effect from 25mg evident from day after administration: Persistent treatment effect of 58% of patients in 25mg arm received apparent after both first and second 25mg arm over full 26 weeks retreatment after Week 9 fixed doses in Part A

  13. Slide 13: COMP006 - COMP360 Response Can Be Rapid and Durable – Unique in TRD

    COMP006 - COMP360 Response Can Be Rapid and Durable – Unique in TRD 39% of participants in 25mg arm achieved clinically 28% of those who achieved clinically meaningful meaningful reduction in MADRS* at Week 6 and on reduction in MADRS but had not remitted by 6 weeks average maintained response at le

  14. Slide 14: COMP006 - Majority of AEs Transient and Occurred on Day of Administration

    COMP006 - Majority of AEs Transient and Occurred on Day of Administration COMP360 COMP360 COMP360 COMP360 COMP360 COMP360 25 mg 10 mg 1 mg COMP006 Through 26 25 mg 10 mg 1 mg COMP006 Through 26 Weeks Weeks N=296 N=142 N=143 (>10% Incidence in 25mg) N=296 N=142 N=143 n (%) n (%) n (%) MedDRA TEAE Pre

  15. Slide 15: COMP006 - SAEs Similar in 25mg and 1mg Arms and Low in Number Overall

    COMP006 - SAEs Similar in 25mg and 1mg Arms and Low in Number Overall COMP360 COMP360 COMP360 COMP360 COMP360 COMP360 25 mg 10 mg 1 mg 25 mg 10 mg 1 mg MedDRA TEAE MedDRA TEAE N=296 N=142 N=143 N=296 N=142 N=143 Preferred Term Preferred Term n (%) n (%) n (%) n (%) n (%) n (%) Any TESAE 17 (5.7) 5 (

  16. Slide 16: COMP360 Generally Well-Tolerated with Safe Profile

    COMP360 Generally Well-Tolerated with Safe Profile ❖ COMP360 generally safe and well-tolerated • Majority of AEs transient and occurring on day of administration ❖ Safety data consistent with known profile of COMP360 psilocybin • No new safety signals identified ❖ SAEs similar in 25mg and 1mg arms a

  17. Slide 17: Commercial Update

    Commercial Update © Compass Pathways | 17

  18. Slide 18: 1 in 3 Patients Drug-Treated for MDD are Considered Treatment Resistant

    1 in 3 Patients Drug-Treated for MDD are Considered Treatment Resistant1 Epidemiology of TRD ~23M MDD Prevalence of US adults experiencing MDD each year1 MDD- Adult patients who are drug treated for ~12M treated patients MDD in the past year 1 Generally accepted definition of TRD: MDD patients faile

  19. Slide 19: TRD is Associated with a Greater Burden Compared to MDD

    TRD is Associated with a Greater Burden Compared to MDD Longer depressive episodes6 Increased relapse rates and decreased remission rates3,4,7 STAR*D Study (2006)3,7∞ Real-world Claims (2024)4† N = 4,041 N = 110,406 1st MDD 200 65% episode 49% 53% 45% 1st TRD 571 42% episode 31% 0 100 200 300 400 50

  20. Slide 20: Emerging Profile of COMP360 has Potential to Revolutionize how Mental Health Conditions are Treated

    Emerging Profile of COMP360 has Potential to Revolutionize how Mental Health Conditions are Treated Durability Unprecedented durability Clinically meaningful sustained through at least efficacy in a patient Remarkable with 6 months with only 1 or 2 population with limited Consistency infrequent addi

  21. Slide 21: Anticipated Timeline to COMP360 Launch, if FDA Approved

    Anticipated Timeline to COMP360 Launch, if FDA Approved Breakthrough FDA rolling Anticipated Therapy review and completion of Anticipated designation National Priority rolling NDA launch, if FDA granted by the FDA Voucher granted submission approved October April Q4 H1 2018 2026 2026 2027 Advanced c

  22. Slide 22: Well-established Infrastructure of Interventional Psychiatry Treatment Centers in Place

    Well-established Infrastructure of Interventional Psychiatry Treatment Centers in Place and Preparing to Offer COMP360 ~7,500 Spravato® treatment clinics in US 1 Centers Established Practice Patterns 578 Dedicated rooms/areas for treatments that require multi-hour monitoring Operational and scheduli

  23. Slide 23: COMP360: Transforming Mental Health Care

    COMP360: Transforming Mental Health Care Blockbuster Opportunity1 Upcoming Catalysts Large underserved markets in TRD (4M Completion of NDA submission in Q4 U..S. patients) & PTSD (13M U.S. patients) 2026: Expected launch H1 2027 Compelling Data Provider Scalability 2 successful Ph3 TRD trials: rapi

  24. Slide 24: Thank you… Q&A

    Thank you… Q&A For more information: Stephen Schultz SVP, Investor Relations stephen.schultz@compasspathways.com +1 401-290-7324 © Compass Pathways | 24

Compass Pathways — Corporate Update (July 2026) on 6ix